Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: There is no proven role for adjuvant medical therapy after curative surgery (R0) for GEP-NENs.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Rossi R
Authors: Rossi R, Altomare M, Monteleone M, Prinzi N, Pusceddu S,
Keywords: radical surgery, recurrence, gastro-entero-pancreatic neuroendocrine neoplasms, prognostic factors,
Introduction: Many different therapies are suggested by guidelines to treat loco-regionally advanced or metastatic G1-G2 neuroendocrine tumors (NETs). However, a precise therapeutic algorithm has not yet been established.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Faggiano A, Di Maio S, Tafuto S, Mocerino C, Di Sarno A,
Keywords: neuroendocrine tumor, medical therapy, sequence of treatments,
Introduction: Bronchial Carcinoids (BCs) are rare neuroendocrine neoplasms arising from respiratory epithelium. The only effective treatment option is surgery, but its efficacy is frequently limited by metastatic spread. Everolimus prolongs progression free survival but patients may develop resistance. Previous studies demonstrated that Everolimus reduces viability of NCI-H720 cells (Atypical Carcinoid) but not of NCI-H727 cells (Typical Carcinoid). Everolimus decreases Ciclyn D1 protein levels in both cell lines but NCI-H727 cells survive, indicating a derangement in cell cycle control.
Conference: 15th Annual ENETSConcerence (2018)
Presenting Author:
Authors: Bresciani G, Riva E, Ambrosio M, Zatelli M,
Keywords: bronchial carcinoids, cell cycle, cyclins, cdks, target therapy, everolimus, dinaciclib, palbociclib,
#1550 Very Early Response to Sunitinib in VHL Patient with Pancreatic Neuroendocrine Tumor
Introduction: Pancreatic neuroendocrine tumors (pNET) arise in 8-17% of Von Hippel Lindau (VHL) patients and surgery plays a key role for resectable lesions. Alternative medical therapy, such as target therapy (TT), can be used when surgery is unfeasible
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: Caff A
Authors: Caff A, Cittadini G, De Cian F, Sciallero S, Malandrino P,
Keywords: VHL therapy,
#1494 CDK-Inhibitors as New Therapeutic Treatment for Human Bronchial Carcinoids
Introduction: Bronchial Carcinoids (BC) are still orphan of medical therapy. We previously demonstrated that 70% of primary BC cultures are sensitive to Everolimus (E), an mTOR inhibitor, while 30% are not. We also observed that in 2 human BC cell lines, the NCI-H720 (sensitive to E) and NCI-H727 (resistant to E), mTOR resistance may be linked to a differential cell cycle protein expression (CyclinD1/E, CDK2/4, p27kip1/p27kip1phospho-Ser10), which is higher in BC resistant to E as compared to sensitive ones, suggesting an impaired p27 function
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author: BENFINI K
Authors: Benfini K, Gentilin E, Riva E, Di Pasquale C, Falletta S,
Keywords: Bronchial Carcinoid, Medical Therapy, mTOR Resistance, CDK inhibitors,